Skip to content

Brown Adipose Tissue Activity in Pre- and Postmenopausal Women

The Impact of Estrogen Status on the Biological Function of Brown Adipose Tissue in Women Measured Using Quantitative PET/CT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02927392
Enrollment
69
Registered
2016-10-07
Start date
2017-03-16
Completion date
2023-05-02
Last updated
2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause, Obesity

Brief summary

The physiological relevance of brown adipose tissue (BAT) in humans is largely unknown. The investigators have shown that suppressing ovarian function in premenopausal women reduces resting energy expenditure (REE), and this is prevented by adding back estradiol (E2). The investigators preliminary data suggest that this may be due, in part, to reduced brown adipose tissue (BAT) activity. The overarching hypothesis is that BAT activity in humans is modulated by E2. To determine if natural declines in endogenous E2 contribute to changes in BAT activity, we will compare BAT activity in pre-and post-menopausal women. The investigators will also explore whether suppression of ovarian hormones in pre-menopausal women impairs BAT activity. BAT activity will be quantified using dynamic positron emission topography/computed tomography (PET/CT) imaging combined with 11C-acetate tracers. We will assess the thermogenic response of BAT by measuring cold-induced changes in REE, shivering, and skin and core temperature.

Detailed description

Participants will be asked to perform studies to measure resting metabolic rate and activity of brown adipose tissue or brown fat. Brown fat is different from regular white fat in that it produces heat and burns calories. The investigators will measure how active brown fat is at normal room temperature and after participants have been exposed to cold. The study will last 5-6 hours. It will consist of measurements made in warm temperatures and then after a period of cold exposure. For the cold exposure part of the study, participants will be asked to wear a cooling suit for 3 hrs. Skin temperature is normally about 90º Fahrenheit. The cooling suit will adjust the water temperature until your skin temperature is about 82º Fahrenheit. The suit will cover the entire body except for the face, hands, and feet. Participants may feel cold while wearing the suit and you may shiver some, but based on past studies, any shivering should be minor. Before and after the cooling suit is turned on, body scans will be performed using a procedure called positron emission tomography (PET). These scans do not use radiation. Before the PET scans, the investigators will infuse radioactive tracer into an arm. These tracers have a low dose of radiation and will show us where the brown fat is and how active it is. One PET scan will be performed at room temperature, and the second scan will be performed after the cooling suit has been worn for 3 hours. Two additional scans using computed tomography (CT) will be performed at end of the study. CT scans are like an x-ray, and use radiation. The radiation dose in the CT scan is much higher than the tracers. When the CT scans are combined with the PET scans, we can separate brown fat from white fat. 15 pre-menopausal women will be asked to volunteer for a follow up study. For 5 months, pre-menopausal women in this study will receive monthly injections that contain a study drug (leuprolide) that reduces estrogen to postmenopausal levels. This drug is approved by the FDA to reduce estrogen for the treatment of uterine fibroids and endometriosis, but is not approved for use in healthy women. In this study, the drug is being used to decrease hormones to determine if this reduces brown fat activity. 6 months after the first injection, these women will be asked to repeat the PET/CT studies.

Interventions

DRUGLeuprolide acetate

A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).

Sponsors

University of Ottawa
CollaboratorOTHER
Université de Sherbrooke
CollaboratorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Premenopausal volunteers will be healthy, eumenorrheic women, aged 18-45 yrs. Eumenorrheic status will be verified by regular menses (no missed cycles in previous year; cycle length 25-35 d). * Postmenopausal volunteers will be healthy women who have no menses for at least 12 months

Exclusion criteria

\- Body mass index (BMI) \> 35 kg/m2 Additional

Design outcomes

Primary

MeasureTime frameDescription
Brown Adipose Tissue Volume5-6 hrsBrown adipose tissue volume will be measured using the radioactive tracer 18Fluro-deoxyglucose.
Brown Adipose Tissue Activity -Warm Exposure5-6 hrsBrown adipose tissue activity in warm temperatures will be measured using the radioactive tracer 11C-acetate
Brown Adipose Tissue Activity - ColdExposure5-6 hrsBrown adipose tissue activity after cold exposure will be measured using the radioactive tracer 11C-acetate

Secondary

MeasureTime frameDescription
Resting Energy Expenditure - Before Cold Exposure5-6 hrs.Resting energy expenditure is the calories burned when a person is at rest.
Resting Energy Expenditure - After Cold Exposure5-6 hrsResting energy expenditure is the calories burned when a person is at rest.

Countries

United States

Participant flow

Participants by arm

ArmCount
Pre-menopausal Women
To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity. Leuprolide acetate: A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
28
Post-menopausal Women
To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
25
Total53

Baseline characteristics

CharacteristicPost-menopausal WomenTotalPre-menopausal Women
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
10 Participants10 Participants0 Participants
Age, Categorical
Between 18 and 65 years
15 Participants43 Participants28 Participants
Age, Continuous64 years
STANDARD_DEVIATION 8
49 years
STANDARD_DEVIATION 16
35 years
STANDARD_DEVIATION 9
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Black or African American
0 Participants1 Participants1 Participants
Race (NIH/OMB)
More than one race
1 Participants4 Participants3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants4 Participants1 Participants
Race (NIH/OMB)
White
20 Participants42 Participants22 Participants
Region of Enrollment
United States
25 participants53 participants28 participants
Sex: Female, Male
Female
25 Participants53 Participants28 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 280 / 25
other
Total, other adverse events
0 / 280 / 25
serious
Total, serious adverse events
0 / 280 / 25

Outcome results

Primary

Brown Adipose Tissue Activity - ColdExposure

Brown adipose tissue activity after cold exposure will be measured using the radioactive tracer 11C-acetate

Time frame: 5-6 hrs

ArmMeasureValue (MEAN)Dispersion
Pre-menopausal WomenBrown Adipose Tissue Activity - ColdExposure1.277 disintegration per minute (dpm)Standard Deviation 0.851
Post-menopausal WomenBrown Adipose Tissue Activity - ColdExposure.906 disintegration per minute (dpm)Standard Deviation 0.544
Primary

Brown Adipose Tissue Activity -Warm Exposure

Brown adipose tissue activity in warm temperatures will be measured using the radioactive tracer 11C-acetate

Time frame: 5-6 hrs

ArmMeasureValue (MEAN)Dispersion
Pre-menopausal WomenBrown Adipose Tissue Activity -Warm Exposure.557 disintegration per min (dpm)Standard Deviation 0.309
Post-menopausal WomenBrown Adipose Tissue Activity -Warm Exposure.631 disintegration per min (dpm)Standard Deviation 0.283
p-value: <0.0001ANOVA
Primary

Brown Adipose Tissue Volume

Brown adipose tissue volume will be measured using the radioactive tracer 18Fluro-deoxyglucose.

Time frame: 5-6 hrs

ArmMeasureValue (MEAN)Dispersion
Pre-menopausal WomenBrown Adipose Tissue Volume53.1 mLStandard Deviation 42.5
Post-menopausal WomenBrown Adipose Tissue Volume20.6 mLStandard Deviation 29.7
Secondary

Resting Energy Expenditure - After Cold Exposure

Resting energy expenditure is the calories burned when a person is at rest.

Time frame: 5-6 hrs

ArmMeasureValue (MEAN)Dispersion
Pre-menopausal WomenResting Energy Expenditure - After Cold Exposure93.6 kcal/hStandard Deviation 25.3
Post-menopausal WomenResting Energy Expenditure - After Cold Exposure85.0 kcal/hStandard Deviation 19.3
Secondary

Resting Energy Expenditure - Before Cold Exposure

Resting energy expenditure is the calories burned when a person is at rest.

Time frame: 5-6 hrs.

ArmMeasureValue (MEAN)Dispersion
Pre-menopausal WomenResting Energy Expenditure - Before Cold Exposure1334 kcal/dayStandard Deviation 205
Post-menopausal WomenResting Energy Expenditure - Before Cold Exposure1223 kcal/dayStandard Deviation 189

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026